Acetic Acid → (S)-5-(4-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-2-fluorobenzamide

HRID 2170343Notes

Reaction equation

HRID 2170343 reaction equation
[F:1][CH:2]([F:53])[C:3]1[C:11]2[C:10]([F:13])([F:12])[CH2:9][CH2:8][C:7]([F:15])([F:14])[C:6]=2[N:5]([CH2:16][C:17]([NH:19][C@H:20]([C:30]2[C:35]([C:36]3[CH:37]=[CH:38][C:39]([F:45])=[C:40]([CH:44]=3)[C:41]([NH2:43])=[O:42])=[CH:34][N:33]=[C:32]([N:46]3[CH2:51][CH2:50][C:49](=[O:52])[CH2:48][CH2:47]3)[N:31]=2)[CH2:21][C:22]2[CH:27]=[C:26]([F:28])[CH:25]=[C:24]([F:29])[CH:23]=2)=[O:18])[N:4]=1.C(O)(=O)C.C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+].CCOC(C)=O>ClCCCl.O>[F:53][CH:2]([F:1])[C:3]1[C:11]2[C:10]([F:12])([F:13])[CH2:9][CH2:8][C:7]([F:14])([F:15])[C:6]=2[N:5]([CH2:16][C:17]([NH:19][C@H:20]([C:30]2[C:35]([C:36]3[CH:37]=[CH:38][C:39]([F:45])=[C:40]([CH:44]=3)[C:41]([NH2:43])=[O:42])=[CH:34][N:33]=[C:32]([N:46]3[CH2:47][CH2:48][CH:49]([OH:52])[CH2:50][CH2:51]3)[N:31]=2)[CH2:21][C:22]2[CH:27]=[C:26]([F:28])[CH:25]=[C:24]([F:29])[CH:23]=2)=[O:18])[N:4]=1

Participants

7

Reactant 4

HCID 176Acetic AcidHCID 8857Ethyl AcetateHCID 5049666Sodium triacetoxyborohydrideHCID 90281442(S)-5-(4-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-2-(4-oxopiperidin-1-yl)pyrimidin-5-yl)-2-fluorobenzamide

Product 1

HCID 90281234(S)-5-(4-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl)-2-fluorobenzamide

Reagents, catalysts & solvents 2

HCID 111,2-DichloroethaneSolventHCID 962WaterSolvent

Procedure

To a solution of compound 19C (18 mg, 0.023 mmol) in 1,2-dichloroethane (0.5 ml), was added acetic acid (13 μL, 0.23 mmol) and sodium triacetoxyborohydride (9.7 mg, 0.046 mmol) at room temperature. After being stirred for 3 hours, the mixture was treated with EtOAc (10 mL) and water (3 mL). The organic layer was washed with brine (2 mL), dried (MgSO4), filtered, and concentrated under reduced pressure to furnish the crude product. This material was purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford the title product. 1H NMR (400 MHz, CD3OD) δ 8.71 (d, J=8.5 Hz, 1H), 8.09 (s, 1H), 7.41 (dd, J=7.0, 2.3 Hz, 1H), 7.33 (m, 1H), 7.20 (dd, J=10.8, 8.5 Hz, 1H), 6.97-6.61 (m, 3H), 6.42 (d, J=6.2 Hz, 2H), 5.24 (t, J=7.2 Hz, 1H), 5.13-4.96 (m, 2H), 4.51 (m, 2H), 4.01-3.83 (m, 1H), 3.42 (m, 2H), 3.14-2.82 (m, 2H), 2.50 (m, 4H), 2.08-1.84 (m, 2H), 1.68-1.37 (m, 2H); MS (m/z) 756.22 [M+H]+.

Workup

  1. washThe organic layer was washed with brine (2 mL)
  2. dry with materialdried (MgSO4)
  3. filtrationfiltered
  4. concentrationconcentrated under reduced pressure
  5. customto furnish the crude product
  6. customThis material was purified on reverse phase HPLC
  7. washeluting with acetonitrile and water (with 0.1% TFA)

Sources & evidence

ORD record
ord-14fa772ee9c74f62966547579408c778
Source dataset
uspto-grants-2015_06
Patent number
US09050344B2

Reaction notes

Loading…